SW · LONN.SW · MEDICAL - DIAGNOSTICS & RESEARCH
Lonza Group AG (LONN.SW) intrinsic value and stock valuation
$651.20as of 2026-11-21 · Mkt cap 34.73B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Lonza Group AG DCF and intrinsic value
InvestorsCraft values LONN.SW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LONN.SW’s statements →
Lonza Group AG Graham Number
Graham Number: $199.57d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.53B | $6.57B | $6.72B | $6.22B | $5.41B |
| Operating income | $1.38B | $964M | $880M | $1.54B | $851M |
| Net income | $949M | $636M | $654M | $1.22B | $2.94B |
| EPSd | $13.5M | $8.92M | $8.88M | $16.3M | $39.5M |
| Operating cash flow | $1.17B | $1.27B | $1.39B | $1.04B | $1.22B |
| Capital expenditure | -$-1.37B | -$-1.42B | -$-1.65B | -$-1.87B | -$-1.35B |
| Free cash flow | -$-204M | -$-143M | -$-263M | -$-833M | -$-126M |
| Total assets | $19B | $19.7B | $16.8B | $17.4B | $16.5B |
| Total debt | $4.19B | $5.12B | $3.13B | $2.59B | $2.75B |
| Net debt | $3.47B | $4.01B | $1.66B | $1.25B | $1.17B |
| Total equity | $9.19B | $9.39B | $9.51B | $10.7B | $9.82B |
| Cash and short-term investments | $719M | $1.71B | $1.67B | $2.22B | $3.18B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.53B | $6.57B | $6.72B | $6.22B | $5.41B |
| Cost of revenue | $4.22B | $4.41B | $4.77B | $3.79B | $3.3B |
| Gross profit | $2.31B | $2.16B | $1.95B | $2.44B | $2.11B |
| Research and development expenses | $0.00 | $0.00 | $105M | $95M | $90M |
| Selling, general and administrative expenses | $765M | $945M | $837M | $827M | $754M |
| Other expenses | $186M | $251M | $126M | -$-25M | $415M |
| Operating expenses | $951M | $1.2B | $1.07B | $897M | $1.26B |
| Cost and expenses | $5.16B | $5.61B | $5.84B | $4.68B | $4.56B |
| Interest income | $42M | $40M | $38M | $6M | $3M |
| Interest expense | $162M | $155M | $108M | $73M | $72M |
| Depreciation and amortization | $47M | $647M | $621M | $596M | $522M |
| Ebitda | $1.31B | $1.54B | $1.53B | $2.12B | $1.38B |
| Operating income | $1.38B | $964M | $880M | $1.54B | $851M |
| Total other income/expenses, net | -$-281M | -$-210M | -$-90M | -$-93M | -$-91M |
| Income before tax | $1.1B | $754M | $790M | $1.45B | $760M |
| Income tax expense | $192M | $117M | $135M | $230M | $83M |
| Net income | $949M | $636M | $654M | $1.22B | $2.94B |
| Weighted average shares outstanding | $70.2M | $71.2M | $73.7M | $74.2M | $74.3M |
| Weighted average diluted shares outstanding | $70.2M | $71.3M | $73.7M | $74.4M | $74.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $719M | $1.71B | $1.67B | $2.22B | $3.18B |
| Net receivables | $1.78B | $1.57B | $1.43B | $1.49B | $1.14B |
| Inventory | $1.68B | $1.73B | $1.59B | $1.82B | $1.5B |
| Total current assets | $8B | $5.44B | $4.9B | $5.71B | $5.93B |
| Property, plant and equipment, net | $8.3B | $8.53B | $6.62B | $6.12B | $4.69B |
| Goodwill and intangible assets | $2.29B | $5.37B | $4.74B | $7.96B | $8.43B |
| Long-term investments | $0.00 | $264M | $305M | $298M | $281M |
| Total non-current assets | $11B | $14.3B | $12.2B | $11.6B | $10.5B |
| Total assets | $19B | $19.7B | $16.8B | $17.4B | $16.5B |
| Accounts payable | $0.00 | $406M | $468M | $477M | $483M |
| Short-term debt | $309M | $512M | $227M | $732M | $219M |
| Deferred revenue | $0.00 | $0.00 | $745M | $649M | $667M |
| Total current liabilities | $3.57B | $3.58B | $2.76B | $3.08B | $2.37B |
| Long-term debt | $3.88B | $4.61B | $2.91B | $1.86B | $2.53B |
| Deferred revenue, non-current | $0.00 | $1.01B | $658M | $739M | $675M |
| Total non-current liabilities | $6.21B | $6.77B | $4.57B | $3.61B | $4.27B |
| Capital lease obligations | $0.00 | $410M | $331M | $355M | $346M |
| Total liabilities | $9.78B | $10.3B | $7.34B | $6.69B | $6.64B |
| Common stock | $70M | $72M | $74M | $74M | $74M |
| Retained earnings | $9.92B | $9.49B | $9.49B | $9.04B | $7.98B |
| Accumulated other comprehensive income (loss) | -$-1.8B | -$-1.28B | -$-1.5B | -$-987M | -$-815M |
| Total equity | $9.19B | $9.39B | $9.51B | $10.7B | $9.82B |
| Total investments | $0.00 | $864M | $505M | $1.18B | $1.88B |
| Total debt | $4.19B | $5.12B | $3.13B | $2.59B | $2.75B |
| Net debt | $3.47B | $4.01B | $1.66B | $1.25B | $1.17B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $949M | $636M | $654M | $1.22B | $674M |
| Depreciation and amortization | $0.00 | $0.00 | $621M | $596M | $522M |
| Stock-based compensation | $0.00 | $0.00 | $21M | $32M | $45M |
| Change in working capital | -$-384M | -$-200M | $1M | -$-581M | -$-278M |
| Accounts receivable | $0.00 | -$-108M | -$-35M | -$-252M | -$-292M |
| Inventory | $0.00 | $0.00 | $143M | -$-343M | -$-381M |
| Accounts payable | $0.00 | $3M | -$-6M | -$-2M | $213M |
| Net cash provided by operating activities | $1.17B | $1.27B | $1.39B | $1.04B | $1.22B |
| Investments in property, plant and equipment | -$-1.37B | -$-1.38B | -$-1.68B | -$-1.87B | -$-1.35B |
| Acquisitions, net | -$-56M | -$-1.07B | -$-93M | $235M | $72M |
| Net cash used for investing activities | -$-732M | -$-2.92B | -$-1.1B | -$-991M | $1.02B |
| Common stock issued | $11M | $9M | $9M | $7M | $0.00 |
| Common stock repurchased | -$-518M | -$-769M | -$-1.02B | -$-58M | -$-174M |
| Dividends paid | -$-280M | -$-288M | -$-260M | -$-223M | -$-225M |
| Net cash used for financing activities | -$-755M | $1.28B | -$-152M | -$-286M | -$-1.28B |
| Net change in cash | -$-392M | -$-357M | $129M | -$-243M | $963M |
| Cash at end of period | $719M | $1.11B | $1.47B | $1.34B | $1.58B |
| Operating cash flow | $1.17B | $1.27B | $1.39B | $1.04B | $1.22B |
| Capital expenditure | -$-1.37B | -$-1.42B | -$-1.65B | -$-1.87B | -$-1.35B |
| Free cash flow | -$-204M | -$-143M | -$-263M | -$-833M | -$-126M |
Line items
Line items
Line items
About Lonza Group AG
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.
- CEO
- Wolfgang Wienand
- Employees
- 18K
- Beta
- 0.82
Included in
Explore
Frequently asked questions
What is the intrinsic value of Lonza Group AG (LONN.SW)?
InvestorsCraft does not currently publish an intrinsic value for LONN.SW. How the IC value is calculated.
Is LONN.SW undervalued?
InvestorsCraft does not publish an undervaluation signal for LONN.SW at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.